



The Current Status and Trend of Clinical Pharmacology and Clinical Care

Guest Editors:

Dr. Imran Kazmi

Department of Biochemistry,
Faculty of Science, King
Abdulaziz University, Jeddah
21589, Makkah, Saudi Arabia

Prof. Dr. Sanmoy Karmakar

Bioequivalence Study Centre,
Department of Pharmaceutical
Technology, Jadavpur University,
Kolkata 700032, India

Md. Adil Shaharyar

Bioequivalence Study Centre,
Department of Pharmaceutical
Technology, Jadavpur University,
Kolkata 700032, India

Deadline for manuscript
submissions:

closed (1 November 2023)

Message from the Guest Editors

Dear Colleagues,

Clinical pharmacology encompasses human investigations through randomised controlled trials (RCTs) and evaluating benefit–risk ratios in large populations. In the realm of precision medicine, identifying novel disease phenotypes and endotypes will presumably be helpful in locating new pharmacological targets, patients who respond well to treatments, and patients at risk for adverse drug reactions. On the other hand, developing nucleic acids and phytomolecule-based vaccines and modulating various players of the immune system to address multiple diseases is still a grey area.

We invite you to contribute with an original review or research paper, to highlight any of the following: (i) clinical immunology; (ii) research based on traditional formulations already in clinical use for modifying the immune system; (iii) vaccine development and clinical trials in a wide variety of diseases in humans; (iv) phytomolecule- and nucleic acid-based vaccine drug delivery, development and challenges; or (v) recent advances in novel prophylactic and therapeutic vaccines in clinical trials.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com